The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases

Progress in Neurobiology

Volumn 125, Issue , 2015, Pages 26-46

  Wright, John W ^a,b   Kawas, Leen H ^a,b   Harding, Joseph W ^a,b  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b M3 Biotechnology Inc   (United States)

Author keywords

Alzheimer's disease; Angiotensin IV; AT4 receptor subtype; C Met receptor; Dihexa; Hepatocyte growth factor; Parkinson's disease

Indexed keywords

AMINOPEPTIDASE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 4 RECEPTOR; ANGIOTENSIN II [3-8]; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CHOLINESTERASE INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN REGULATED AMINOPEPTIDASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; RECEPTOR SUBTYPE; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; ANGIOTENSIN II; ANGIOTENSIN II, DES-ASP(1)-DES-ARG(2)-ILE(5)-; AT4 RECEPTOR;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; COGNITION; HUMAN; LEARNING; MEMORY; MOTOR PERFORMANCE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN STRUCTURE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; COMPLICATION; DRUG EFFECTS; MEMORY DISORDERS; METABOLISM; PHYSIOLOGY;

ALZHEIMER DISEASE; ANGIOTENSIN II; ANIMALS; HUMANS; MEMORY DISORDERS; PARKINSON DISEASE; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 84922267253     PISSN: 03010082     EISSN: 18735118     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2014.11.004     Document Type: Review

References (386)

1. Abounader R., Laterra J. Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro Oncol. 2005, 7:436-451.
2. Aizawa K., Sato S., Terakawa M., Saitoh D., Tsuda H., Ashida H., Obara M. Accelerated adhesion of grafted skin by laser-induced stress wave-based gene transfer of hepatocyte growth factor. J. Biomed. Opt. 2009, 14:064043.
3. Akimoto M., Baba A., Ikeda-Matsuo Y., Yamada M.K., Itamura R., Nishiyama N., Ikegaya Y., Matsuki N. Hepatocyte growth factor as an enhancer of NMDA currents and synaptic plasticity in the hippocampus. Neuroscience 2004, 128:155-162.
4. Albiston A.L., Diwakaria S., Fernando R.N., Mountford S.J., Yeatman H., Morgan B., Pham V., Holien J.K., Parker M.W., Thompson P.E., Chai S.Y. Identification and development of specific inhibitors for insulin-regulated aminopeptidase as a new class of cognitive enhancers. Br. J. Pharmacol. 2011, 164:37-47.
5. Albiston A.L., Fernando R.N., Yeatman H.R., Burns P., Ng I., Daswani D., Diwakarla S., Pham V., Chai S.Y. Gene knock-out of insulin-regulated aminopeptidase: loss of the specific binding site for angiotensin IV and age related deficit in spatial memory. Neurobiol. Learn. Mem. 2010, 93:19-30.
6. Albiston A.L., McDowall S.G., Matsacos D., Sim P., Clune E., Mustafa T., Lee J., Mendelsohn F.A., Simpson R.J., Connolly L.M., Chai S.Y. Evidence that the angiotensin IV (AT4) receptor is the enzyme insulin regulated aminopeptidase. J. Biol. Chem. 2001, 276:48263-48266.
7. Albiston A.L., Morton C.J., Ng H.I., Pham V., Yeatman H.R., Ye S., Fernando R.N., De Bundel D., Ascher D.B., Mendelsohn F.A., Parker M.W., Chai S.Y. Identification and characterization of a new cognitive enhancer based on inhibition of insulin-regulated aminopeptidase. FASEB J. 2008, 22:4209-4217.
8. Albiston A.L., Mustafa T., McDowall S.G., Mendelsohn F.A., Lee J., Chai S.Y. AT(4) receptor is insulin-regulated aminopeptidase: potential mechanisms of memory enhancement. Trends Endocrinol. Metab. 2003, 14:72-77.
9. Albiston A.L., Pederson E.S., Burns P., Purcell B., Wright J.W., Harding J.W., Mendelsohn F.A., Weisinger R.S., Chai S.Y. Attenuation of scopolamine-induced learning deficits by LVV-hermorphin-7 in rats in the passive avoidance and water maze paradigms. Behav. Brain Res. 2004, 154:239-243.
10. Allen A.M., MacGregor D.P., Chai S.Y., Donnan G.A., Daczmarczyk S., Richardson K., Kainins R., Ireton J., Mendelsohn F.A. Angiotensin II receptor binding associated with nigrostriatal dopaminergic neurons in human basal ganglia. Ann. Neurol. 1992, 32:339-344.
11. Allen A.M., Moeller I., Jenkings T.A., Zhuo J., Aldred G.P., Chai S.Y., Mendelsohn F.A. Angiotensin receptors in the nervous system. Brain Res. Bull. 1998, 47:17-28.
12. Allen A.M., Oldfield B.J., Giles M.E., Paxinos G., McKinley M.J., Mendelsohn F.A. Localization of angiotensin receptors in the nervous system. Handbook of Chemical Neuroanatomy 2000, 79-124. Elsevier, Amsterdam. R. Quirion, A. Bjorklund, T. Hodfelt (Eds.).
13. Amenta F., Di Tullio M.A., Tomassoni D. The cholinergic approach for the treatment of vascular dementia: evidence from pre-clinical and clinical studies. Clin. Exp. Hypertens. 2002, 24:697-713.
14. Andersson H., Demaegdt H., Johnsson A., Vauquelin G., Lindeberg G., Hallberg M., Endelyl M., Karten A., Hallberg A. Potent macrocyclic inhibitors of insulin-regulated aminopeptidase (IRAP) by olefin ring-closing metathesis. J. Med. Chem. 2011, 54:3779-3792.
15. Andersson H., Demaegdt H., Vauquelin G., Lindeberg G., Karlen A., Hallberg M. Ligands to the (IRAP)/AT4 receptor encompassing a 4-hydroxydiphenylmethane scaffold replacing Tyr2. Bioorg. Med. Chem. 2008, 16:6924-6935.
16. Andersson H., Demaegdt H., Vauquelin G., Lindeberg G., Karten A., Hallberg M., Erdelyl M., Hallberg A. Disulfide cyclized tripeptide analogues of angiotensin IV as potent and selective inhibitors of insulin-regulated aminopeptidase (IRAP). J. Med. Chem. 2010, 53:8059-8071.
17. Andersson H., Hallberg M. Discovery of inhibitors of insulin-regulated aminopeptidase as cognitive enhancers. Int. J. Hypertens. 2012, 12. ID 789671.
18. Ascherio A., Tanner C.M. Use of antihypertensives and the risk of Parkinson disease. Neurology 2009, 72:578-579.
19. Ashby E.L., Kehoe P.G. Current status of renin-aldosterone angiotensin system-targeting anti-hypertensive drugs as therapeutic options for Alzheimer's disease. Expert Open. Invest. Drugs 2013, 22:1229-1242.
20. Babior B.M. NADPH oxidase. Curr. Open. Immunol. 2004, 16:42-47.
21. Bae M.H., Bissonette G.B., Mars W.M., Michalopoulos G.K., Achim C.L., Depireux D.A., Powell E.M. Hepatocyte growth factor (HGF) modulates GABAergic inhibition and seizure susceptibility. Exp. Neurol. 2010, 221:129-135.
22. Basillico C., Amesano A., Galluzzo M., Comoglio P.M., Michieli P. A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met. J. Biol. Chem. 2008, 283:21267-21277.
23. Basso N., Paglia N., Stella I. Protective effect of the inhibition of the renin-angiotensin system on aging. Regul. Pept. 2005, 128:247-252.
24. Bauer J.H. Angiotensin converting enzyme inhibitors. Am. J. Hypertens. 1990, 3:331-337.
25. Béchard D., Gentina T., Delehedde M., Scherpereel A., Lyon M., Aumercier M., Vazeux R., Richet C., Degand P., Jude B., Janin A., Fernig D.G., Tonnei A.B., Lassalie P. Endocan is a novel chondroitin sulfate/dermatan sulfate proteoglycan that promotes hepatocyte growth factor/scatter actor mitogenic activity. J. Biol. Chem. 2001, 276:48341-48349.
26. Becker C., Jick S.S., Meier C.R. Use of antihypertensives and the risk of Parkinson disease. Neurology 2008, 70(6):438-444.
27. Bennett J.P., Snyder S.H. Angiotensin II binding to mammalian brain membranes. J. Biol. Chem. 1976, 251:7423-7430.
28. Benoist C.C., Kawas L.H., Zhu M., Tyson K.A., Stillmaker L., Appleyard S.M., Wright J.W., Wayman G.A., Harding J.W. The pro-cognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-Met system. J. Pharmacol. Exp. Ther. 2014, 351:390-402.
29. 1-angiotensin IV analogs. J. Pharmacol. Exp. Ther. 2011, 339:35-44.
30. 4 receptor from bovine aortic endothel photosensitive analogues of angiotensin IV. Biochemistry 1998, 37:4280-4287.
31. Bernier S.G., Fournier A., Guillemette G. A specific binding site recognizing a fragment of angiotensin II in bovine adrenal cortex membranes. Eur. J. Pharmacol. 1994, 271:55-63.
32. Bild W., Hritcu L., Stefanescu C., Ciobica A. Inhibition of central angiotensin II enhances memory function and reduces oxidative stress status in rat hippocampus. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 43:79-88.
33. Birchmeier C., Birchmeier W., Gherardi E., Vande Woude G.F. Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 2003, 4:915-925.
34. Birchmeier C., Gherardi E. Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol. 1998, 8:404-410.
35. 2 receptors do not interact with guanine nucleotide binding proteins. Eur. J. Pharmacol. 1991, 207:157-163.
36. Bottaro D.P., Rubin J.D., Faletto D.L., Chan A.M., Kmiecik T.E., Vande Woude G.F., Aaronson S.A. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991, 251:802-804.
37. 2 dopamine receptor blockade prevents cognitive effects of AngIV and des-Phe6 AngIV. Physiol. Behav. 2006, 88:152-159.
38. Braszko J.J., Kupryszewski G., Witczuk B., Wisniewski K. Angiotensin II (3-8)-hexapeptide affects motor activity, performance of passive avoidance, and a conditioned avoidance response in rats. Neuroscience 1988, 27:777-783.
39. Braszko J.J., Walesiuk A., Wielgat P. Cognitive effects attributed to angiotensin II may result from its conversion to angiotensin IV. J. Renin Angiotensin Aldosterone Syst. 2006, 7:168-174.
40. Braszko J.J., Wielgat P., Walesiuk A. Effect of D(3) dopamine receptor blockade on the cognitive effects of angiotensin IV in rats. Neuropeptides 2008, 42:301-309.
41. Braszko J.J., Wlasienko J., Koziolkiewicz W., Janecka A., Wisniewski K. The 3-7 fragment of angiotensin II is probably responsible for its psychoactive properties. Brain Res. 1991, 542:49-54.
42. Braun-Menendez E., Fasiolo J.C., Leioir L.F., Munoz J.M. The substance causing renal hypertension. J. Physiol. 1940, 98:283-298.
43. Brayne C., Matthews F.E., Xuereb J.H. Pathological correlates of late onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet 2001, 357:169-175.
44. Brett A.C., Rosenstock T.R., Rego A.C. Current therapeutic advances in patients and experimental models of Huntington's disease. Curr. Drug Targets 2014, 15:313-334.
45. Brunner H.R., Gavras H., Laragh J.H., Keenan R. Angiotensin II blockade in man by SAR ALA angiotensin II for understanding and treatment of high blood pressure. Lancet 1973, 2:1045-1048.
46. Buccafusco J.J. Emerging cognitive enhancing drugs. Expert Open. Emerg. Drugs 2009, 14:577-589.
47. Buggy J., Johnson A.K. Angiotensin-induced thirst: effects of third ventricle obstruction and periventricular ablation. Brain Res. 1978, 149:117-128.
48. Bumpus F.M., Schwarz H., Page I.H. Synthesis and pharmacology of the octapeptide angiotonin. Science 1957, 125:886-887.
49. Bumpus F.M., Schwarz H., Page I.H. Synthesis and properties of angiotonin. Circulation 1958, 17:664-667.
50. Chabrashvili T., Kitilyakara C., Blau J., Karber A., Asiam S., Welch W.J., Wilcox C.S. Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2003, 285:R117-R124.
51. 4 receptor) in the human forebrain, midbrain and pons as visualized by in vitro receptor autoradiography. J. Chem. Neuroanat. 2000, 20:339-348.
52. Chai S.Y., Christie M.J., Beart P.M., Mendelsohn F.A. Effects of nigral dopaminergic lesions and striatal excitotoxin lesions on brain converting enzyme. Neurochem. Int. 1987, 10:101-107.
53. Chai S.Y., McKenzie J.S., McKinley M.J., Mendelsohn F.A. Angiotensin converting enzyme in the human basal forebrain and midbrain visualized by in vitro autoradiography. J. Comp. Neurol. 1990, 291:179-194.
54. 4 receptor. CMLS Cell. Mol. Life Sci. 2004, 61:2728-2737.
55. Chai S.Y., Yeatman H.R., Parker M.W., Ascher C.B., Thompson P.E., Mulvey H.T., Albiston A.L. Development of cognitive enhancers based on inhibition of insulin-regulated aminopeptidase. BMC Neurosci. 2008, 9(Suppl. 2):S2-S14.
56. Chaudhuri K.R., Odin P., Antonini A., Martinez-Martin P. Parkinson's disease: the non-motor issues. Parkinsonism Relat. Disord. 2011, 17:717-723.
57. Chaudhuri K.R., Shapira A.H. The non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 2009, 8:464-474.
58. Chauvel E.N., Llorens-Cortes C., Coric P., Wilk S., Roques B.P., Fournie-Zaluski M.C. Differential inhibition of aminopeptidase A and aminopeptidase N by new beta-amino thiols. J. Med. Chem. 1994, 37:2950-2957.
59. Chen M., Maleski J.J., Sawmiller D.R. Scientific truth or false hope: understanding Alzheimer's disease from an aging perspective. J. Alzheimers Dis. 2011, 24:3-10.
60. Chirgadze D.Y., Heppie J.P., Zhou H., Byrd R.A., Blundell T.L., Gherardi E. Crystal structure of the NK1 fragment of HGF/SF suggests a novel mode for growth factor dimerization and receptor binding. Nat. Struct. Biol. 1999, 6:72-79.
61. Christensen D.D. Changing the course of Alzheimer's disease: emerging modifying therapies. Curr. Psychiatry Rev. 2006, 2:179-188.
62. Clark C.M. Clinical manifestations and diagnostic evalulation of patients with Alzheimer's disease. Neurodegenerative Dementias: Clinical Features and Pathological Mechanisms 2000, 95-114. McGraw-Hill, New York, NY. C.M. Clark, J.Q. Trajanowski (Eds.).
63. Collier T.J., Kipton J., Daley F., Palfi S., Chu Y., Sortwell C., Collier T.J., Carvey P.M. Aging-related changes in the nigrostriatal dopamine system and the response to MPTP in nonhuman primates: diminished compensatory mechanisms as a prelude to Parkinsonism. Neurobiol. Dis. 2007, 26:56-65.
64. Combs D., D'Alecy I. Motor performance in rats exposed to severe forebrain ischemia: effect of fasting and 1,3-butanediol. Stroke 1987, 18:503-511.
65. Conway K., Price P., Harding K.G., Jiang W.G. The molecular and clinical impact of hepatocyte growth factor, its receptor, activators, and inhibitors in wound healing. Wound Repair Regen. 2006, 14:2-10.
66. Conway K., Ruge F., Price P., Harding K.G., Jiang W.G. Hepatocyte growth factor regulation: an integral part of why wounds become chronic. Wound Repair Regen. 2007, 15:683-692.
67. Cortes C.J., La Spada A.R., 2014 The many faces of autophagy dysfunction in Huntington's disease: from mechanism to therapy. Drug Discov. Today 2014, Epub ahead of print.
68. Croog S.H., Levine S., Testa M.A., Brown B., Bulpitt C.J., Jenkins C.D., Klerman G.L., Williams G.H. The effects of antihypertensive therapy on the quality of life. N. Engl. J. Med. 1986, 314:1657-1674.
69. Cruz-Muros I., Afonso-Oramas D., Abreu P., Perez-Delgado M.M., Rodriguez M., Gonzalez-Hernandez T. Aging effects on the dopamine transporter expression and compensatory mechanisms. Neurobiol. Aging 2009, 30:973-986.
70. Cummings J.L. Biomarkers in Alzheimer's disease drug development. Alzheimers Dement. 2011, 7:e13-e44.
71. Dai C., Li Y., Hang J., Liu Y. Hepatocyte growth factor preserves beta cell mass and mitigates hyperglycemia in streptozotocin-induced diabetic mice. J. Biol. Chem. 2003, 278:27080-27087.
72. Dai C., Huh C.G., Thorgeirsson S.S., Liu Y. Beta-cell-specific ablation of the hepatocyte growth factor receptor results in reduced islet size, impaired insulin secretion, and glucose intolerance. Am. J. Pathol. 2005, 167:429l-436l.
73. Dalmay F., Pesteil F., Allard J., Nisse-Durgeat S., Fernandez L., Fournier A. Angiotensin IV decreases acute stroke mortality in the gerbil. Hypertension 2001, 14:56A.
74. Dasgupta C., Zhang L. Angiotensin II receptors and drug discovery in cardiovascular disease. Drug Discov. Today 2011, 16:22-34.
75. Date I., Takagi N., Takagi K., Kago T., Matsumoto K., Nakamura T., Takeo S. Hepatocyte growth factor attenuates cerebral ischemia-induced learning dysfunction. Biochem. Biophys. Res. Commun. 2004, 319:1152-1158.
76. Date I., Takagi N., Takagi K., Kago T., Matsumoto K., Nakamura T., Takeo S. Hepatocyte growth factor improved learning and memory dysfunction of microsphere-embolized rats. J. Neurosci. Res. 2004, 78:442-543.
77. Davis C.J., Kramár E.A., De A., Meighan P.D., Simasko S.M., Wright J.W., Harding J.W. AT4 receptor activation increases intracellular calcium influx and induces a non-N-methyl-d-aspartate dependent form of long-term potentiation. Neuroscience 2006, 137:1369-1379.
78. 1 receptor subtype in the effects of angiotensin IV and LVV-haemorphin 7 on hippocampal neurotransmitter levels and spatial working memory. J. Neurochem. 2010, 112:1223-1234.
79. De Bundel D., Smolders I., Vanderheyden P., Michotte Y. AngII and AngIV: unraveling the mechanism of action on synaptic plasticity, memory, and epilepsy. CNS Neurosci. Ther. 2008, 14:315-339.
80. De Bundel D., Smolders I., Yang R., Albiston A.L., Michotte Y., Chai S.Y. Angiotensin IV and LVV-haemorphin 7 enhance spatial working memory in rats: effects on hippocampal glucose levels and blood flow. Neurobiol. Learn. Mem. 2009, 92:19-26.
81. Demaegdt H., De Backer J.P., Lukaszuk A., Tóth G., Szemenyei E., Tourwe D., Vauquelin G. Angiotensin IV displays only low affinity for native insulin-regulated aminopeptidase (IRAP). Fundam. Clin. Pharmacol. 2012, 26:194-197.
82. Demaegdt H., Lukaszuk A., De Buyser E., De Backer J.P., Szemenyei E., Tóth G., Chakravarthy S., Panicker M., Michotte Y., Tourwe D., Vauquelin G. Selective labeling of IRAP by the tritiated AT4 receptor ligand [3H] Angiotensin IV and its stable analog [3H]AL-11. Mol. Cell. Endocrinol. 2009, 311:77-86.
83. de Gasparo M., Catt K.J., Inagami T., Wright J.W., Unger T. International Union of Pharmacology. XXIII. The angiotensin II receptors. Pharmacol. Rev. 2000, 52:415-472.
84. de Gasparo M., Husain A., Alexander W., Catt K.J., Chiu A.T., Drew M., Goodfriend T., Harding J.W., Inagami T., Timmermans P.B. Proposed update of angiotensin receptor nomenclature. Hypertension 1995, 25:924-939.
85. De Rijk M.C., Launer L.J., Berger K., Breteler M.M., Dartigues J.F., Baidereschi M., Fratiglioni L., Lobo A., Martinez-Lage J., Trenkwalder C., Hofman A. Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurologic diseases in the elderly research group. Neurology 2000, 54(Suppl. 5):S21-S23.
86. Derksen P.W., de Gorter D.J., Meijer H.P., Bende R.J., van Dijk M., Lokhorst H.M., Bloem A.C., Spaargaren M., Pals S.T. The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma. Leukemia 2003, 17:764-774.
87. Deuschl G., Schade-Brittinger C., Krack P., Valkmann J., Schafer H., Botzel K. A randomized trial of deep-brain stimulation for Parkinson's disease. N. Engl. J. Med. 2006, 355:896-908.
88. Dirnberger G., Jahanshahi M. Executive dysfunction in Parkinson's disease; a review. J. Neuropsychol. 2013, 7:193-224.
89. Ding Q., Dimayuga E., Keller J.N. Proteasome regulation of oxidative stress in aging and age-related disease of the CNS. Antioxid. Redox Signal. 2006, 8:163-172.
90. Dinh D.T., Grauman A.G., Johston C.I., Fabiani M.E. Angiotensin receptors: distribution, signaling and function. Clin. Sci. 2001, 100:481-492.
91. Doeppner T.R., Kaltwasser B., EiAli A., Zechariah A., Hermann D.M., Bahr M. Acute hepatocyte growth factor treatment induces long-term neuroprotection and stroke recovery via mechanisms involving neural precursor cell proliferation and differentiation. J. Cereb. Blood Flow Metab. 2011, 31:1251-1262.
92. Doody R.S., Dunn J.K., Clark C.M., Farlow M., Foster N.L., Liao T., Gonzales N., Lai E., Massman P. Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2001, 12:295-300.
93. Doraiswamy P.M., Xiong G.L. Pharmacological strategies for the prevention of Alzheimer's disease. Expert Open. Pharmacother. 2006, 7:1-10.
94. Eder J.P., Vande Woude G.F., Boemer S.A., LoRusso P.M. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin. Cancer Res. 2009, 15:2207-2214.
95. Ehlers M.R., Riordan J.F. Angiotensin-converting enzyme: new concepts concerning its biological role. Biochemistry 1989, 28:5311-5318.
96. Ehringer H., Horaykieuicz O. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. Klin. Wochenschr. 1960, 38:1236-1239.
97. Eklind-Cervenka M., Benson L., Dahlstrom U., Edner M., Rosenqvist M., Lund L.H. Association of candesartan vs losartan with all-cause mortality in patients with heart failure. JAMA 2011, 305:175-182.
98. Ellul J., Archer N., Foy C.M., Poppe M., Boothby H., Nicholas H., Brown R.G., Lovestone S. The effects of commonly prescribed drugs in patients with Alzheimer's disease on the rate of deterioration. J. Neurol. Neurosurg. Psychiatry 2006, 78:233-239.
99. Faure S., Chapot R., Tallet D., Javellaud J., Achard J.M., Oudart N. Cerebroprotective effect of angiotensin IV in experimental ischemic stroke in the rat mediated by AT(4) receptors. J. Physiol. Pharmacol. 2006, 57:329-342.
100. Fernando R.N., Albiston A.L., Chai S.Y. The insulin-regulated aminopeptidase IRAP is colocalized with GLUT4 in the mouse hippocampus - potential role in modulation of glucose uptake in neurons?. Eur. J. Neurosci. 2008, 28:588-598.
101. Fernando R.N., Larm J., Albiston A.L., Chair S.Y. Distribution and cellular localization of insulin-regulated aminopeptidase in the rat central nervous system. J. Comp. Neurol. 2005, 487:372-390.
102. Ferrario C.M., Chappell M.D. Novel angiotensin peptides. Cell. Mol. Life Sci. 2004, 61:2720-2727.
103. Fitzsimons J.T. Angiotensin stimulation of the central nervous system. Rev. Physiol. Biochem. Pharmacol. 1980, 87:117-167.
104. Fogari R., Mugellini A., Zoppi A., Derosa G., Pasotti C., Fogari E., Preti P. Influence of losartan and atenolol on memory function in very elderly hypertensive patients. J. Hum. Hypertens. 2003, 17:781-785.
105. Freund M., Walther T., von Bohlen und Halbach O. Immunohistochemical localization of the angiotensin-(1-7) receptor Mas in the murine forebrain. Cell Tissue Res. 2012, 348:29-35.
106. Funakoshi H., Nakamura T. Hepatocyte growth factor: from diagnosis to clinical applications. Clin. Chim. Acta 2003, 327:1-23.
107. Furlong R.A., Takehara T., Taylor W.G., Nakamura T., Rubin J.S. Comparison of biological and immunochemical properties indicates that scatter factor and hepatocyte growth factor are indistinguishable. J. Cell Sci. 1991, 100:173-177.
108. Fyhrquist F., Saijonmaa O. Renin-angiotensin system revisited. J. Intern. Med. 2008, 264:224-236.
109. Galimberti D., Scarpini E. Alzheimer's disease: from pathogenesis to disease-modifying approaches. CNS Neurol. Disord. Drug Targets 2011, 10:163-174.
110. Ganten D., Boucher R., Genest J. Renin activity in brain tissue of puppies and adult dogs. Brain Res. 1971, 33:557-559.
111. Ganten D., Marquez-Julio A., Granger P., Hayduk K., Karsunky K.P., Boucher R., Genest J. Renin in dog brain. Am. J. Physiol. 1971, 221:1733-1737.
112. Garcia Ruiz P.J. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study. Mov. Disord. 2008, 23:1130-1136.
113. Gard P.R. The role of angiotensin II in cognition and behaviour. Eur. J. Pharmacol. 2002, 438:1-14. 2002.
114. Gard P.R. Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression. Expert Open. Ther. Targets 2004, 8:7-14.
115. Gard P.R. Cognitive-enhancing effects of angiotensin IV. BMC Neurosci. 2008, 9(Suppl. 2):S2-S15.
116. Gard P.R., Olivier G., Golding B., Bourner C., Dang T., Haliru H., Higgins E., Kimberley H., Loginova O., Madhavi S., Ryan D. Assessment of biological activity of novel peptide analogues of angiotensin IV. Pharm. Pharmacol. 2011, 63:565-571.
117. Geldmacher D.S., Kerson N.Y., Birnbaum H.G., Eapen S., Kantor E., Cummings A.K., Joish V.N. Implications of early treatment among Medicaid patients with Alzheimer's disease. Alzheimers Dement. 2014, 10:214-224.
118. Gherardi E., Sandin S., Petoukhov M.V., Finch J., Youles M.E., Ofverstedt L.G., Miguel R.N., Blundell T.L., Vande Woude G.F., Skoglund U., Svergun D.I. Structural basis of hepatocyte growth factor/scatter factor and MET signaling. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:4046-4051.
119. Gherardi E., Youles M.E., Miguel R.N., Blundell T.L., Lamele L., Gough J., Bandyopadhyay A., Hartmann G., Butler P.J. Functional map and domain structure of MET, the product of the c-met protoon-cogene and receptor for hepatocyte growth factor/scatter factor. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:12039-12044.
120. Gordon P., Corcia P., Meininger V. New therapy options for amyotrophic lateral sclerosis. Expert Open. Pharmacother. 2013, 14:1907-1917.
121. Grammatopoulos T.N., Jones S.M., Ahmadi F.A., Hoover B.R., Snell L.D., Skoch J., Javeri V.V., Poczobutt A.M., Weyhenmeyer J.A., Zawada W.M. Angiotensin type 1 receptor antagonist losartan, reduces MPTP-induced degeneration of dopaminergic neurons in substantia nigra. Mol. Neurodegener. 2007, 2:1-17.
122. Grammatopoulos T.N., Outeiro T.F., Hyman B.T., Standaert D.G. Angiotensin II protects against α-synuclein toxicity and reduces protein aggregation in vitro. Biochem. Biophys. Res. Commun. 2007, 363:846-851.
123. Griendling K.K., Sorescu D., Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ. Res. 2000, 86:494-501.
124. Gutierrez H., Dolcet X., Tolcos M., Davies A. HGF regulates the development of cortical pyramidal dendrites. Development 2004, 131:3717-3726.
125. Ha X.Q., Lv T.D., Hui L., Dong F. Effects of mesenchymal stem cells transfected with human hepatocyte growth factor gene on healing of burn wounds. Chin. J. Traumatol. 2010, 13:349-355.
126. Haber E. The role of renin in normal and pathological cardiovascular homeostasis. Circulation 1976, 54:849-861.
127. Hajjar I.M., Keown M., Frost B. Antihypertensive agents for aging patients who are at risk for cognitive dysfunction. Curr. Hypertens. Rep. 2005, 7:466-473.
128. Hajjar I.M., Keown M., Lewis P., Almor A. Angiotensin converting enzyme inhibitors and cognitive and functional decline in patients with Alzheimer's disease: an observational study. Am. J. Alzheimers Dis. Other Demen. 2008, 23:77-83.
129. Hamanoue M., Takemoto N., Matsumoto K., Nakamura T., Nakajima K., Kohsaka S. Neurotrophic effect of hepatocyte growth factor on central nervous system neurons in vitro. J. Neurosci. Res. 1996, 43:554-564.
130. Handa R.K. Angiotensin-(1-7) can interact with the rat proximal tubule AT(4) receptor system. Am. J. Physiol. 1999, 277:F75-F83.
131. Hanes D.S., Weir M.R. Usefulness of ARBs and ACE inhibitors in the prevention of vascular dementia in the elderly. Am. J. Geriatr. Cardiol. 2007, 16:175-182.
132. Hanesworth J.M., Sardinia J.F., Krebs L.T., Hall K.L., Harding J.W. Elucidation of a specific binding site for angiotensin II(3-8), angiotensin IV, in mammalian heart membranes. J. Pharmcol. Exp. Ther. 1993, 266:1036-1042.
133. Harding J.W., Cook V.I., Miller-Wing A.V., Hanesworth J.M., Sardinia M.F., Hall K.L., Stobb J.W., Swanson G.N., Coleman J.K., Wright J.W., Harding E.C. Identification of an AII (3-8) [AIV] binding site in guinea pig hippocampus. Brain Res. 1992, 583:340-343.
134. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
135. Hashimoto N., Yamanaka H., Fukuoka T., Obata K., Mashimo T., Naguchi K. Expression of hepatocyte growth factor in primary sensory neurons of adult rats. Brain Res. Mol. Brain Res. 2001, 97:83-88.
136. Hellner K., Walther T., Schubert M., Albrecht D. Angiotensin-(1-7) enhances LTP in the hippocampus through the G protein-coupled receptor Mas. Mol. Cell. Neurosci. 2005, 29:427-435.
137. Herrmann N., Chau S.A., Kircanski I., Lanctót L. Current and emerging drug treatment options for Alzheimer's disease. Drugs 2011, 71:2013-2056.
138. Holmes O., Pillozzi S., Deakin J.A., Carafoli F., Kemp L., Butler P.J., Lyon M., Gherardi E. Insights into the structure/function of hepatocyte growth factor/scatter factor from studies with individual domains. J. Mol. Biol. 2007, 367:395-408.
139. Honig L.S., Boyd C.D. Treatment of Alzheimer's disease: current management and experimental therapeutics. Curr. Transl. Geniatr. Exp. Gerontol. Rep. 2013, 2:174-181.
140. Hossain M.A., Russell J.C., Gomez R., Laterra J. Neuroprotection by scatter factor/hepatocyte growth factor and FGF-1 in cerebellar granule neurons is phosphatidylinositol 3-kinase/akt-dependent and MAPK/CREB-independent. J. Neurochem. 2002, 81:365-378.
141. Hurd M.D., Martorell P., Dalevande A., Mullen K.J., Panga M. Monetary costs of dementia in the United States. N. Engl. J. Med. 2013, 368:1326-1334.
142. Imbimbo B.P., Giardina G.A. γ{phonetic}-Secretase inhibitors and modulators for the treatment of Alzheimer's disease: disappointments and hopes. Curr. Top. Med. Chem. 2011, 11:1555-1570.
143. Ishigaki A., Aoki M., Nagai M., Warita H., Kato S., Kato M. Intrathecal delivery of hepatocyte growth factor from amyotrophic lateral sclerosis onset suppresses disease progression in rat amyotrophic lateral sclerosis model. J. Neuropathol. Exp. Neurol. 2007, 66:1037-1044.
144. Janda E., Isidoro C., Carresi C., Mollace V. Defective autophagy in Parkinson's disease: role of oxidative stress. Mol. Neurobiol. 2012, 46:639-661.
145. 2 recognition sites in bovine adrenal cortex. Eur. J. Pharmacol. 1992, 219:319-322.
146. Jenkins T.A., Mendelsohn F.A., Chai S.Y. Angiotensin-converting enzyme modulates dopamine turnover in the striatum. J. Neurochem. 1997, 68(3):1304-1311.
147. Jenkins T.A., Wong J.Y., Howells D.W., Mendelsohn F.A., Chai S.Y. Effect of chronic angiotensin-converting enzyme inhibition on striatal dopamine content in the MPTP-treated mouse. J. Neurochem. 1999, 73:214-219.
148. Joglar B., Rodriguez-Pallares J., Rodriguez-Perez A.I., Rey P., Guerra M.J., Labandeira-Garcia J.L. The inflammatory response in the MPTP model of Parkinson's disease is mediated by brain angiotensin: relevance to progression of the disease. J. Neurochem. 2009, 109:656-669.
149. Johnson A.K., Epstein A.N. The cerebral ventricles as the avenue for the dipsogenic action of intracranial angiotensin. Brain Res. 1975, 86:399-418.
150. Johnston C.I. Biochemistry and pharmacology of the renin-angiotensin system. Drugs 1990, 39:21-31.
151. Jones E.S., Vinh A., McCarthy C.A., Gaspari T.A., Widdop R.E. AT2 receptors: functional relevance in cardiovascular disease. Pharmacol. Ther. 2008, 120:292-316.
152. Kaduszkiewicz H., Zimmermann T., Beck-Bomholdt H.P., van den Bussche H. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomized clinical trials. BMJ 2005, 331:321-327.
153. Kambayashi Y., Bardhan S., Takahashi K., Tsuzuki S., Inui T., Hamakubo T., Inagami Y. Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. J. Biol. Chem. 1993, 268:24543-24546.
154. Kato T., Funakoshi H., Kadoyamea K., Noma S., Kanai M., Ohya-Shimada W., Mixuno S., Doe N., Taniguchi T., Nakamura T. Hepatocyte growth factor overexpression in the nervous system enhances learning and memory performance in mice. J. Neurosci. Res. 2012, 90:1743-1755.
155. Kaushik D.K., Basu A. A friend in need may not be a friend indeed: role of microglia in neurodegenerative diseases. CNS Neurol. Disord. Drug Targets 2013, 12:726-740.
156. Kawas L.H., Benoist C.C., Harding J.W., Wayman G.A., Abu-Lail N.I. Nanoscale mapping of the Met receptor on hippocampal neurons by AFM and confocal microscopy. Nanomedicine 2013, 9:428-438.
157. Kawas L.H., McCoy A.T., Yamamoto B.J., Wright J.W., Harding J.W. Development of angiotensin IV analogs as hepatocyte growth factor/Met modifiers. J. Pharmacol. Exp. Ther. 2012, 340:539-548.
158. Kawas L.H., Yamamoto B.J., Wright J.W., Harding J.W. Mimics of the dimerization domain of hepatocyte growth factor exhibit anti-Met and anticancer activity. J. Pharmacol. Exp. Ther. 2011, 339:509-518.
159. Kehoe P.G., Wilcock G.K. Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease?. Lancet Neurol. 2007, 6:373-378.
160. Kerins D.M., Hao Q., Baughan D.E. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J. Clin. Invest. 1995, 96:2515-2520.
161. Khachaturian A.S., Zandi P.P., Lyketsos C.G., Hayden K.M., Skoog I., Norton M.C., Tschanz J.T., Mayer L.S., Welsh-Bohmer K.A., Breitner J.C. Antihypertensive medication use and incident Alzheimer disease: the Cache County study. Arch. Neurol. 2006, 63:686-692.
162. Khosla M.C., Leese R.A., Maloy W.L., Ferreira A.T., Smeby R.R., Bumpus F.M. Synthesis of some analogs of angiotensin II as specific antagonists of the parent hormone. J. Med. Chem. 1972, 15:792-795.
163. Kinoshita T., Hirao S., Matsumoto K., Nakamura T. Possible endocrine control by hepatocyte growth factor of liver regeneration after partial hepatectomy. Biochem. Biophys. Res. Commun. 1991, 17:330-335.
164. Kjeldsen S.E., Stlhammar J., Hasvold P., Bodegard J., Olsson U., Russell D. Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension. J. Hum. Hypertens. 2010, 24:263-273.
165. Kobori T., Goda K., Sugimoto K., Ota T., Tomisawa K. Preparation of peptide derivatives as angiotensin IV receptor agonists. WO 97/03093 A1 1997.
166. Kobori T., Goda K., Sugimoto K., Ota T., Tomisawa K. Preparation of amino acid derivatives as angiotensin IV receptor agonists. WO 98/05624 A1 1998.
167. Koike H., Ishida A., Shimamura M., Mizuno S., Nakamura T., Ogihara T. Prevention of onset of Parkinson's disease by in vivo gene transfer of human hepatocyte growth factor in rodent model: a model of gene therapy for Parkinson's disease. Gene Ther. 2006, 13:1639-1644.
168. Koike H., Morishita R., Iguchi S., Aoki M., Matsumoto K., Nakamura T. Enhanced angiogenesis and improvement of neuropathy by cotransfection of human hepatocyte growth factor and prostacyclin synthase gene. FASEB J. 2003, 17:779-781.
169. Korhonen L., Sjoholm U., Takei N., Kern M.A., Schirmacher P., Castren E., Lindholm D. Expression of c-Met in developing rat hippocampus: evidence for HGF as a neurotrophic factor for calbindin D-expressing neurons. Eur. J. Neurosci. 2000, 12:3453-3461.
170. Kramár E.A., Armstrong D.L., Ikeda S., Wayner M.J., Harding J.W., Wright J.W. The effects of angiotensin IV analogs on long-term potentiation within the CA1 region of the hippocampus in vitro. Brain Res. 2001, 897:114-121.
171. Kramár E.A., Harding J.W., Wright J.W. Angiotensin II- and IV-induced changes in cerebral blood flow. Roles of AT1, AT2, and AT4 receptor subtypes. Regul. Pept. 1997, 68:131-138.
172. Kramár E.A., Krishnan R., Harding J.W., Wright J.W. Role of nitric oxide in angiotensin IV-induced increases in cerebral blood flow. Regul. Pept. 1998, 74:185-192.
173. Krebs L.T., Kramar E.A., Hanesworth J.M., Sardinia M.F., Ball A.E., Wright J.W., Harding J.W. Characterization of the binding properties and physiological action of divalinal-angiotensin IV, a putative AT4 receptor antagonist. Regul. Pept. 1996, 67:123-130.
174. Kuniyasu H., Yasui W., Kitadai Y., Yokozaki H., Ito H., Tahara E. Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem. Biophys. Res. Commun. 1992, 189:227-232.
175. Labandeira-Garcia J.L., Rodriguez-Pallares J., Villar-Cheda B., Rodriquez-Perz A.I., Garrido-Gil P., Guerra M.J. Aging, angiotensin system and dopaminergic degeneration in the substantia nigra. Aging Dis. 2011, 2:257-274.
176. Laeremans H., Demaegdt H., De Backer J.P., Le M.T., Kersemans V., Michotte Y., Vauquelin G., Vanderheyden P.M. Metal ion modulation of cystinyl aminopeptidase. Biochem. J. 2005, 390:351-357.
177. Lan F., Xu J., Zhang X., Wong V.W., Li X., Lu A., Lu W., Shen L., Li L. Hepatocyte growth factor promotes proliferation and migration in immortalized progenitor cells. Neuroreport 2008, 19:765-769.
178. Lee J., Albiston A.L., Allen A.M., Mendelsohn F.A., Ping S.E., Barrett G.L., Murphy M., Morris M.J., McDowall S.G., Chai S.Y. Effect of ICV injection of AT4 receptor ligands, NLE1 angiotensin IV and LVV-hemorphin 7, on spatial learning in rats. Neuroscience 2004, 124:341-349.
179. Lee J., Chai S.Y., Mendelsohn F.A., Morris M.J., Allen A.M. Potentiation of cholinergic transmission in the rat hippocampus by angiotensin IV and LVV-hemorphin-7. Neuropharmacology 2001, 40:618-623.
180. Lee J., Mustafa T., McDowall S.G., Mendelsohn F.A., Brennan M., Lew R.A., Albiston A.L., Chai S.Y. Structure-activity study of LVV-hemorphin-7: angiotensin AT4 receptor ligand and inhibitor of insulin-regulated aminopeptidase. J. Pharmacol. Exp. Ther. 2003, 305:205-211.
181. Lenkei Z., Palkovits M., Corvol P., Llorens-Cortes C. Expression of angiotensin type-1 (AT1) and type-2 (AT2) receptor mRNAs in the adult rat brain: a functional neuroanatomical review. Front. Neuroendocrinol. 1997, 18:383-439.
182. Lew R.A., Mustafa T., Ye S., McDowall S.G., Chai S.Y., Albiston A.L. Angiotensin AT4 ligands are potent, competitive inhibitors of insulin regulated aminopeptidase (IRAP). J. Neurochem. 2003, 86:344-350.
183. Li F., Shetty A.K., Sugahara K. Neuritogenic activity of chondroitin/dermatan sulfate hybrid chains of embryonic pig brain and their mimicry from shark liver. Involvement of the pleiotrophin and hepatocyte growth factor signaling pathways. J. Biol. Chem. 2007, 282:2956-2966.
184. Lietha D., Chirgadze D.Y., Mulloy B., Blundell T.L., Gherardi E. Crystal structures of NK1-heparin complexes reveal the basis for NK1 activity and enable engineering of potent agonists of the MET receptor. EMBO J. 2001, 20:5543-5555.
185. Lipski J., Nistico R., Berretta N., Guatteo E., Bernardi G., Mercuri N.B. A scapegoat for accelerated neurodegeneration in Parkinson's disease?. Prog. Neurobiol. 2011, 94:389-407.
186. Lipton S.A. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism. Curr. Alzheimer Res. 2005, 2:155-165.
187. Lokker N.A., Mark M.R., Luis E.A., Bennett G.L., Robbins K.A., Baker J.B., Godowski P.J. Structure-function analysis of hepatocyte growth factor: identification of variants that lack mitogenic activity yet retain high affinity receptor binding. EMBO J. 1992, 11:2503-2510.
188. Lopez-Real A., Rey P., Soto-Otero R., Mendez-Alvarez E., Labandeira-Garcia J.L. Angiotensin-converting enzyme inhibition reduces oxidative stress and protects dopaminergic neurons in a 6-hydroxydopamine rat model of Parkinsonism. J. Neurosci. Res. 2005, 81:865-873.
189. Lukaszuk A., Demaegdt H., Feytens D., Vanderheyden P., Vauquelin G., Tourwe D. The replacement of His(4) in angiotensin IV by conformationally constrained residues provides highly potent and selective analogues. J. Med. Chem. 2009, 52:5612-5618.
190. Lukaszuk A., Demaegdt H., Szemenyei E., Tóth G., Tymecka D., Misicka A., Karoyan P., Vanderheyden P., Vauquelin G., Tourwe D. Beta-homo-amino acid scan of angiotensin IV. J. Med. Chem. 2008, 51:2291-2296.
191. 6. J. Pept. Sci. 2011, 17:545-553.
192. Lyon M., Deakin J.A., Gallagher J.T. The mode of action of heparin and dermatan sulfates in the regulation of hepatocyte growth factor/scatter factor. J. Biol. Chem. 2002, 277:1040-1046.
193. Lyon M., Deakin J.A., Lietha D., Gherardi E., Gallagher J.T. The interactions of hepatocyte growth factor/scatter factor and its NK1 and NK2 variants with glycosaminoglycans using a modified gel mobility shift assay. Elucidation of the minimal size of binding and activatory oligosaccharides. J. Biol. Chem. 2004, 279:43560-43567.
194. Lyon M., Deakin J.A., Mizuno K., Nakamura T., Gallagher J.T. Interaction of hepatocyte growth factor with heparin sulfate. Elucidation of the major heparin sulfate structural determinants. J. Biol. Chem. 1994, 269:11216-11223.
195. Lyon M., Deakin J.A., Rahmoune H., Fernig D.G., Nakamura T., Gallagher J.T. Hepatocyte growth factor/scatter factor binds with high affinity to dermatan sulfate. J. Biol. Chem. 1998, 273:271-278.
196. Ma P.C., Maulik G., Christensen J., Salgia R. C-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev. 2003, 22:309-325.
197. Maiese K., Chong Z.Z., Hou J., Shang Y.C. New strategies for Alzheimer's disease and cognitive impairment. Oxid. Med. Cell. Longev. 2009, 2:279-289.
198. Marsden C.D. Basal ganglia disease. Lancet 1982, 2:1141-1147.
199. Martins G.J., Plachez C., Powell E.M. Loss of embryonic MET signaling alters profiles of hippocampal interneurons. Dev. Neurosci. 2007, 29:143-158.
200. Marvar P.J., Goodman J., Fuchs S., Choi D.C., Baneiee S., Ressler K.J. Angiotensin type 1 receptor inhibition enhances the extinction of fear memory. Biol. Psychiatry 2013, Epub ahead of print.
201. Matsumoto K., Nakamura T. Hepatocyte growth factor: molecular structure, roles in liver regeneration, and other biological functions. Crit. Rev. Oncog. 1992, 3:27-54.
202. Matsumoto K., Nakamura T. NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics. Cancer Sci. 2003, 94:321-327.
203. Matsumoto K., Nakamura T., Sakai K., Nakamura T. Hepatocyte growth factor and Met in tumor biology and therapeutic approach with NK4. Proteomics 2008, 8:3360-3370.
204. Matzke A., Sargsyan V., Holtmann B., Aramuni G., Asan E., Sendtner M., Pace G., Howells N., Zhang W., Ponta H., Orian-Rousseau V. Haplo insufficiency of c-Met in cd44-/- mice identifies a collaboration of CD44 and c-Met in vivo. Mol. Cell. Biol. 2007, 27:8797-8806.
205. McCoy A.T., Benoist C.C., Wright J.W., Kawas L.H., Bule-Ghogare J.M., Zhu M., Appleyard S.M., Wayman G.A., Harding J.W. Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. J. Pharmacol. Exp. Ther. 2013, 344:141-154.
206. McKinley M.J., Albiston A.L., Allen A.M., Mathai M.L., May C.N., McAllen R.M., Oldfield B.J., Mendelsohn F.A., Chai S.Y. The brain renin-angiotensin system: location and physiological roles. Int. J. Biochem. Cell Biol. 2003, 35:901-918.
207. Mehta P.K., Griendling K.K. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am. J. Physiol. Cell Physiol. 2007, 292:C82-C97.
208. Meighan S.E., Meighan P.C., Choudhury P., Davis C.J., Olson M.L., Zornes P.A., Wright J.W., Harding J.W. Effects of extracellular matrix-degrading proteases matrix metalloproteinases 3 and 9 on spatial learning and synaptic plasticity. J. Neurochem. 2006, 96:1227-1241.
209. Meighan P.C., Meighan S.E., Davis C.J., Wright J.W., Harding J.W. Effects of matrix metalloproteinase inhibition on short- and long-term plasticity of schaffer collateral/CA1 synapses. J. Neurochem. 2007, 102:2085-2096.
210. Meissner W.G., Frasier M., Gasser T., Goetz C.G., Lozano A., Piccini P., Obeso J.A., Rascol O., Shapira A., Voon V., Winer D.M., Tison T., Bezaard E. Priorities in Parkinson's disease research. Nat. Rev. Drug Discov. 2011, 10:377-393.
211. Melnikova I. Therapies for Alzheimer's disease. Nat. Rev. Drug. Discov. 2007, 6:341-342.
212. Mertens B., Vanderheyden P., Michotte Y., Sarre S. The role of the central renin-angiotensin system in Parkinson's disease. J. Renin Angiotensin Aldosterone Syst. 2010, 11:49-56.
213. Michalopoulos G.K., DeFrances M.C. Liver regeneration. Science 1997, 276:60-66.
214. Miguel-Hidalgo J.J., Alvarez X.A., Cacabelos R., Quack G. Neuroprotection by memantine against neurodegeneration induced by beta-amyloid (1-40). Brain Res. 2002, 958:210-221.
215. Miyazawa K., Shimomura T., Kitamura A., Kondo J., Morimoto Y., Kitamura N. Molecular cloning and sequence analysis of the cDNA for a human serine protease responsible for activation of hepatocyte growth factor. Structural similarity of the protease precursor to blood coagulation factor XII. J. Biol. Chem. 1993, 268:10024-10028.
216. Miyazawa T., Matsumoto K., Ohmichi H., Katoh H., Yamashima T., Hakamura T. Protection of hippocampal neurons from ischemia-induced delayed neuronal death by hepatocyte growth factor: a novel neurotrophic factor. J. Cereb. Blood Flow Metab. 1998, 18:345-348.
217. Mizuno S., Matsumoto K., Nakamura T. HGF as a renotrophic and anti-fibrotic regulator in chronic renal disease. Front. Biosci. 2008, 13:7072-7086.
218. Moeller I., Small D.H., Reed G., Harding J.W., Mendelsohn F.A., Chai S.Y. Angiotensin IV inhibits neurite outgrowth in cultured embryonic chicken sympathetic neurons. Brain Res. 1996, 725:61-66.
219. Mogi M., Horiuchi M. Effects of angiotensin II receptor blockers on dementia. Hypertens. Res. 2009, 32:738-740.
220. Morishima-Kawashima M., Oshima N., Ogata H., Yamaguchi H., Yoshimura M., Sugihara S., Ihara Y. Effect of apolipoprotein E allele epsilon4 on the initial phase of amyloid beta-protein accumulation in the human brain. Am. J. Pathol. 2000, 157:2093-2099.
221. Morishita R., Nakamura S., Hayashi S., Taniyama Y., Moriguchi A., Nagano T., Taiji M., Noguchi H., Takeshita S., Matsumoto K., Nakamura T., Higaki J., Ogihara T. Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy. Hypertension 1999, 33:1379-1384.
222. Muleris M., Almeida A., Dutrillaux A.M., Pruchon E., Vega F., Delattre J.Y., Poisson M., Malfoy B., Dutrillaux B. Oncogene amplification in human gliomas: a molecular cytogenetic analysis. Oncogene 1994, 9:2717-2722.
223. Munoz A., Rey P., Guerra M.J. Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of Parkinsonism. Neuropharmacology 2006, 51:112-120.
224. Munzel T., Kearney F.J. Are ACE inhibitors a magic bullet against oxidative stress?. Circulation 2001, 104:1571-1574.
225. Mustafa T., Lee J.H., Chai S.Y., Albiston A.L., McDowall S.G., Mendelsohn F.A. Bioactive angiotensin peptides: focus on angiotensin IV. J. Renin Angiotensin Aldosterone Syst. 2001, 2:205-210.
226. Nakamura T., Mizuno S. The discovery of hepatocyte growth factor (HGF) and its significance for cell biology, life sciences and clinical medicine. Proc. Jpn. Acad., Ser. B Phys. Biol. Sci. 2010, 86:588-610.
227. Nakamura T., Mizuno S., Matsumoto K., Sawa Y., Matsuda H., Nakamura T. Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. J. Clin. Invest. 2000, 106:1511-1519.
228. Nakamura T., Nawa K., Ichihara A. Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem. Biophys. Res. Commun. 1984, 122:1450-1459.
229. Nakamura T., Nishizawa T., Hagiya M., Seki T., Shimonishi M., Sugimura A., Tashiro K., Shimizu S. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989, 342:440-443.
230. Nakajima M., Mukoyama M., Pratt R.E., Horiuchi M., Dzau V.J. Cloning of cDNA and analysis of the gene for mouse angiotensin II type 2 receptor. Biochem. Biophys. Res. Commun. 1993, 197:393-399.
231. Nalivaeva N.N., Fisk L.R., Belyaev N.D., Turner A.J. Amyloid-degrading enzymes as therapeutic targets in Alzheimer's disease. Curr. Alzheimer Res. 2008, 5:212-224.
232. Naveri L., Stromberg C., Saavedra J.M. Angiotensin IV reverses the acute cerebral blood flow reduction after experimental subarachnoid hemorrhage in the rat. J. Cereb. Blood Flow Metab. 1994, 14:1096-1099.
233. Neugroschl J., Sano M. Current treatment and recent clinical research in Alzheimer's disease. Mt. Sinai J. Med. 2010, 77:3-16.
234. Nyholm D. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005, 64:216-223.
235. O'Caoimh R., Healy L., Gao Y., Svendrovski A., Kerins D.M., Eustace J., Kehoe P.G., Guyatt G., Molloy D.W. Effects of centrally acting angiotensin converting enzyme inhibitors on functional decline in patients with Alzheimer's disease. J. Alzheimers Dis. 2014, 40:595-603.
236. Ohishi M., Yamamoto K., Rakugi H. Angiotensin (1-7) and other angiotensin peptides. Curr. Pharm. Des. 2013, 19:3060-3064.
237. Ohno T., French L.C., Hirano S., Ossoff R.H., Rousseau B. Effect of hepatocyte growth factor on gene expression of extracellular matrix during wound healing of the injured rat vocal fold. Ann. Otol. Rhinol. Laryngol. 2008, 117:696-702.
238. Okamura A., Rakugi H., Ohishi M., Yanagitani Y., Takiuchi S., Moriguchi K., Fennessy P.A., Higaki J., Ogihara T. Upregulation of renin-angiotensin system during differentiation of monocytes to macrophages. J. Hypertens. 1999, 17:537-545.
239. Olanow C.W., Stern M.B., Sethi K. The scientific and clinical basis for the treatment of Parkinson disease. Neurology 2009, 72(21 Suppl. 4):S1-S136.
240. 1-angiotensin IV mitigates scopolamine-induced spatial working memory deficits. Peptides 2010, 31:2209-2215.
241. 1-angiotensin IV alleviates mecamylamine-induced spatial memory deficits. Peptides 2004, 25:233-241.
242. Ondetti M.A., Rubin B., Cushman D.W. Design of specific inhibitors of angiotensin converting enzyme: new class of orally active antihypertensive agents. Science 1977, 196:441-444.
243. Page I.H., Helmer O.M. A crystalline pressor substance (angiotonin) resulting from the action between renin and renin-activator. J. Exp. Med. 1940, 71:29-42.
244. Pandya R.S., Zhu H., Li W., Bowser R., Friedlander R.M., Wang X. Therapeutic neuroprotective agents for amyotrophic lateral sclerosis. Cell. Mol. Life Sci. 2013, 70:4729-4745.
245. Parameshwaran K., Dhanasekaran M., Suppiramaniam V. Amyloid beta peptides and glutamaterigic synaptic dysregulation. Exp. Neurol. 2008, 210:7-13.
246. Paris J.J., Eans S.O., Mizrachi E., Reiliey K.J., Ganno M.L., McLaughlin J.P. Central administration of angiotensin IV rapidly enhances novel object recognition among mice. Neuropharmacology 2013, 70:247-253.
247. Passos-Silva D.G., Verano-Braga T., Santos R.A. Angiotensin-(1-7): beyond the cardio-renal actions. Clin. Sci. (Lond) 2013, 124:443-456.
248. 4 receptor subtype in overcoming scopolamine-induced spatial memory deficits. Regul. Pept. 2001, 102:147-156.
249. Pelegrini-Da-Silva A., Rosa E., Guethe L.J., Juliano M.A., Prado W.A., Martins A.R. Angiotensin III modulates the nociceptive control mediated by the periaquaductal gray matter. Neuroscience 2009, 164:1263-1273.
250. Pelicci G., Giordano S., Zhen Z., Salcini A.E., Lanfrancone L., Bardelli A., Panayotou G., Waterfield M.D., Ponzetto C., Pelicci P.G. The motogenic and mitogenic responses to HGF are amplified by the Shc adaptor protein. Oncogene 1995, 10:1631-1638.
251. Peschard P., Ishiyama N., Lin T., Lipkowitz S., Park M. A conserved DpYR motif in the juxtamembrane domain of the Met receptor family forms an atypical c-Cbl/Cbl-b tyrosine kinase binding domain binding site required for suppression of oncogenic activation. J. Biol. Chem. 2004, 279:29565-29571.
252. Phillips M.I. Functions of angiotensin in the central nervous system. Annu. Rev. Physiol. 1987, 49:413-435.
253. Phillips M.I., Felix D. Specific angiotensin II receptive neurons in the cat subfornical organ. Brain Res. 1976, 109:531-540.
254. Polidori M.C., Pientka L. Bridging the pathophysiology of Alzheimer's disease with vascular pathology: the feed-back, the feed-forward, and oxidative stress. J. Alzheimers Dis. 2012, 28:1-9.
255. Ponzetto C., Bardelli A., Zhen Z., Maina F., Dalla Zonca P., Giordano S., Graziani A., Panayotou G., Comoglio P.M. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 1994, 77:261-271.
256. Pouryamout L., Dams J., Wasem J., Dodel R., Neumann A. Economic evaluation of treatment options in patients with Alzheimer's disease: a systematic review of cost-effetiveness analyses. Drugs 2012, 72:789-802.
257. Powell E.M., Muhlfriedel S., Bolz J., Levitt P. Differential regulation of thalamic and cortical axonal growth by hepatocyte growth factor/scatter factor. Dev. Neurosci. 2003, 25:197-206.
258. PROGRESS Collaborative Group Randomized trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001, 358:1033-1041.
259. Prozherina Y.A. Involvement of angiotensin II and angiotensin IV in producing the individual characteristics of defensive and feeding behavior in rats. Neurosci. Behav. Physiol. 2008, 38:563-572.
260. Qin L., Liu Y., Wang T., Wei S.J., Block M.L., Wilson B., Liu B., Hong J.S. NADPH oxidase mediates lipopolysaccharide-induced neurotoxicity and proinflammatory gene expression in activated microglia. J. Biol. Chem. 2004, 279:1415-1421.
261. Re R.N. Mechanisms of disease: local renin-angiotensin-aldosterone systems and the pathogenesis and treatment of cardiovascular disease. Nat. Clin. Pract. Cardiovasc. Med. 2004, 1:42-47.
262. Reardon K.A., Mendelsohn F.A., Chai S.Y., Horne M.K. The angiotensin converting enzyme (ACE) inhibitor, perindopril, modifies the clinical features of Parkinson's disease. Aust. N. Z. J. Med. 2000, 30:48-53.
263. Rey P., Lopez-Real A., Sanchez-Iglesias S., Munoz A., Soto-Otero R., Labandeira-Garcia J.L. Angiotensin type-1-receptor antagonists reduce 6-hydroxydopamine toxicity for dopaminergic neurons. Neurobiol. Aging 2007, 28:555-567.
264. Rich D.H., Moon B.J., Harbeson S. Inhibition of aminopeptidases by amastatin and bestatin derivatives, effect of inhibitor structure on slow-binding processes. J. Med. Chem. 1984, 27:417-422.
265. 3-Angiotensin(1-7) accelerate healing in dermal models. J. Peptide Res. 2006, 66(Suppl. 1):41-47.
266. Rodriguez-Pallares J., Parga J.A., Munoz A., Rey P., Guerra M.J., Labandeira-Garcia J.L. Mechanism of 6-hydroxydopamine neurotoxicity: the role of NADPH oxidase and microglical activation in 6-hydroxydopamine-induced degeneration of dopaminergic neurons. J. Neurochem. 2007, 103:145-156.
267. Rodriguez-Pallares J., Quiroz C.R., Parga J.A., Guerra M.J., Labandeira-Garcia J.L. Angiotensin II increases differentiation of dopaminergic neurons from mesencephalic precursors via angiotensin type 2 receptors. Eur. J. Neurosci. 2004, 20:1489-1498.
268. Rodriguez-Pallares J., Rey P., Parga J.A., Munoz A., Guerra M.J., Labandeira-Garcia J.L. Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS. Neurobiol. Dis. 2008, 31:58-73.
269. Rodriguez-Perez A.I., Valenzuela R., Joglar B., Garrido-Gil P., Guerra M.J., Labandeira-Garcia J.L. Renin angiotensin system and gender differences in dopaminergic degeneration. Mol. Neurodegener. 2011, 6. article 58.
270. Rosario M., Birchmeier W. How to make tubes: signaling by the Met receptor tyrosine kinase. Trends Cell. Biol. 2003, 13:328-335.
271. Rosenmann H. CSF biomarkers for amyloid and tau pathology in Alzheimer's disease. J. Mol. Neurosci. 2012, 47:1-14.
272. Rosenstiel P., Gallinat S., Arit A., Unger T., Sievers J., Lucius R. Angiotensin AT2 receptor ligands: do they have potential as future treatments for neurological disease?. CNS Drugs 2002, 16:145-153.
273. Rozzini L., Chilovi B.V., Bertoletti E., Conti M., Del Rio L., Trabucchi M., Padovani A. Angiotensin converting enzyme (ACE) inhibitors modulate the rate of progression of amnestic mild cognitive impairment. Int. J. Geriat. Psychiatry 2006, 21:550-555.
274. Ruiz-Ortega M., Lorenzo O., Suzuki Y., Rupérez M., Egido J. Proinflammatory actions of angiotensins. Curr. Open. Nephrol. Hypertens. 2001, 10:321-329.
275. Saavedra J.M. Emerging features of brain angiotensin receptors. Regul. Pept. 1999, 85:31-45.
276. Sacena U. Alzheimer's disease amyloid hypothesis at crossroads: where do we go from here?. Expert Open. Ther. Targets 2010, 14:1273-1277.
277. Salehi Z., Rajaei F. Expression of hepatocyte growth factor in the serum and cerebrospinal fluid of patients with Parkinson's disease. J. Clin. Neurosci. 2010, 17:1553-1556.
278. Salloway S., Ferris S., Kluger A., Goldman R., Griesing T., Kumar D., Richardson S., Donepezil 401 Study Group Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. Neurology 2004, 63:651-657.
279. Sandberg K., Ji H., Catt K.J. Regulation of angiotensin II receptors in rat brain during dietary sodium changes. Hypertension 1994, 23:I-137-I-141.
280. Sardinia M.F., Hanesworth J.M., Krebs L.T., Harding J.W. AT4 receptor binding characteristics: d-amino acid- and glycine-substituted peptides. Peptides 1993, 14:949-954.
281. Sardinia M.F., Hanesworth J.M., Krishnan F., Harding J.W. AT4 receptor structure-binding relationship: N-terminal-modified angiotensin IV analogues. Peptides 1994, 15:1399-1406.
282. Sayeski P.P., Ali M.S., Semeniuk D.J., Doan T.N., Bernstein K.E. Angiotensin II signal transduction pathways. Regul. Pept. 1998, 78:19-29.
283. Schapira A.H. Etiology and pathogenesis of Parkinson disease. Neurol. Clin. 2009, 27:583-603.
284. Schneider J.A., Arvanitakis Z., Bang W., Bennett D.A. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007, 69:2197-2204.
285. Schubert D., Maher P. An alternative approach to drug discovery for Alzheimer's disease dementia. Future Med. Chem. 2012, 4:1681-1688.
286. Schwartz C.M., Tayakoli T., Jamias C., Park S.S., Maudsley S., Martin B., Phillips T.M., Yao P.J., Itoh K., Ma W., Rao M.S., Arenas E., Mattson M.P. Stromal factors SDF1α, sFRP1, and BEGFD induce dopaminergic neuron differentiation of human pluripotent stem cells. J. Neurosci. Res. 2012, 90:1367-1381.
287. Seki T., Hagiya M., Shimonishi M., Nakamura T., Shimizu S. Organization of the human hepatocyte growth factor-encoding gene. Gene 1991, 102:213-219.
288. Sepers M.D., Raymond L.A. Mechanisms of synaptic dysfunction and excitotoxicity in Huntington's disease. Drug Discov. Today 2014, Epub ahead of print.
289. Seshiah P.N., Weber D.S., Rocic P., Valppu L., Taniyama Y., Griendling K.K. Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. Circ. Res. 2002, 91:406-413.
290. Shang J., Deguchi K., Ohta Y., Liu N., Zhang X., Tian F., Yamashita T., Ikeda Y., Matsuura T., Funakoshi H., Nakamura T., Abe K. Strong neurogenesis, angiogenesis, synaptogenesis, and antifibrosis of hepatocyte growth factor in rats brain after transient middle cerebral artery occlusion. J. Neurosci. Res. 2011, 89:86-95.
291. Sharma S.K. Hepatocyte growth factor in synaptic plasticity and Alzheimer's disease. Sci. World J. 2010, 10:457-461.
292. Sheth P.R., Hays J.L., Elferink L.A., Watowich S.J. Biochemical basis for the functional switch that regulates hepatocyte growth factor receptor tyrosine kinase activation. Biochemistry 2008, 47:4028-4038.
293. Shi E., Jiang X., Wang L., Akuzawa S., Nakajima Y., Kazui T. Intrathecal injection of hepatocyte growth factor gene-modified marrow stromal cells attenuates neurologic injury induced by transient spinal cord ischemia in rabbits. Anesthesiology 2010, 113:1109-1117.
294. Shimamura M., Sato N., Morishita R. Experimental and clinical application of plasmid DNA in the field of central nervous diseases. Curr. Gene Ther. 2011, 11:491-500.
295. Shimamura M., Sato N., Waguri S., Uchiyama Y., Hayashi T., Iida H., Nakamura T., Ogihara T., Kaneda Y., Morishita R. Gene transfer of hepatocyte growth factor gene improves learning and memory in the chronic stage of cerebral infarction. Hypertension 2006, 47:742-751.
296. Shinomiya N., Vande Woude G.F. Suppression of met expression: a possible cancer treatment. Clin. Cancer Res. 2003, 9(14):5085-5090.
297. Simóes e Silva A.C., Silveira K.D., Ferreira A.J., Teixeira M.M. ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis. Br. J. Pharmacol. 2013, 169:477-492.
298. Simonnet G., Giorguieff-Chesselet M.F., Carayon A., Bioulac B., Cesselin F., Glowinski J., Vincent J.D. Angiotensin II and nigrostriatal system. J. Physiol. (Paris) 1981, 77:71-79.
299. Skeggs L.T., Kahn J.R., Lentz K.E., Shumway N.P. The preparation, purification and amino acid sequence of polypeptide renin substrate. J. Exp. Med. 1957, 106:439-453.
300. Sonnenberg E., Meyer D., Weidner K.M., Birchmeier C. Scatter factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development. J. Cell Biol. 1993, 123:223-235.
301. Soto M.E., van Kan G.A., Nourhashemi F., Gillette-Guyonnet S., Cesari M., Cantet C., Rolland Y., Velias B. Angiotensin-converting enzyme inhibitors and Alzheimer's disease progression in older adults: results from the Reseau sur la Maladie d-Alzheimer Francais cohort. J. Am. Geriatr. Soc. 2013, 61:1482-1488.
302. Speth R.C., Brown T.E., Barnes R.D., Wright J.W. Brain angiotensinergic activity: the state of our current knowledge. Proc. West. Pharmacol. Soc. 2003, 46:11-15.
303. Speth R.C., Karamyan V.T. The significance of brain aminopeptidases in the regulation of the actions of angiotensin peptides in the brain. Heart Fail. Rev. 2008, 13:299-309.
304. Sreedharan J., Brown R.H. Amyotrophic lateral sclerosis: problems and prospects. Ann. Neurol. 2013, 74:309-316.
305. Stamos J., Lazarus R.A., Yao X., Kirchhofer D., Wiesmann C. Crystal structure of the HGF beta-chain in complex with the Sema domain of the Met receptor. EMBO J. 2004, 23:2325-2335.
306. Stoker M., Perryman M. An epithelial scatter factor released by embryo fibroblasts. J. Cell Sci. 1985, 77:209-223.
307. Stragier B., Clinckers R., Meurs A., De Bundel D., Sarre S., Ebinger G., Michotte Y., Smolders I. Involvement of the somatostatin-2 receptor in the anti-convulsant effect of angiotensin IV against pilocarpine-induced limbic seizures in rats. J. Neurochem. 2006, 98:1100-1113.
308. Stragier B., De Bundel D., Sarre S., Smolders I., Vauguelin G., Dupont A., Michotte Y., Vanderheyden P. Involvement of insulin-regulated aminopeptidase in the effects of the renin-angiotensin fragment angiotensin IV: a review. Heart Fail. Rev. 2008, 13:321-337.
309. Stragier B., Sarre S., Vanderheyden P., Vauquelin G., Fournie-Zaluski M.C., Ebinger G., Michotte Y. Metabolism of angiotensin II is required for its in vivo effect on dopamine release in the striatum of the rat. J. Neurochem. 2004, 90:1251-1257.
310. Streeten D.H.P., Anderson G.H., Dalakos T.G. Angiotensin blockade: its clinical significance. Am. J. Med. 1976, 60:817-824.
311. Strittmatter S.M., Thiele E.A., Kapiloff M.S., Snyder S.H. A rat brain isozyme of angiotensin-converting enzyme. Unique specificity for amidated peptide substrates. J. Biol. Chem. 1985, 260:9825-9832.
312. Stubley-Weatherly L., Harding J.W., Wright J.W. Effects of discrete kainic acid-induced hippocampal lesions on spatial and contextual learning and memory in rats. Brain Res. 1996, 716:29-38.
313. Sudilovsky A., Cutler N.R., Sramek J.J., Wardle T., Veroff A.E., Mickelson W., Markowitz J., Repetti S. A pilot clinical trial of the angiotensin-converting enzyme inhibitor ceranapril in Alzheimer's disease. Alzheimer Dis. Assoc. Disord. 1993, 7:105-111.
314. Suehs B.T., Davis C.D., Alvir J., van Ameronnen D., Pharmd N.C., Joshi A.V., Faison W.E., Shah S.N. The clinical and economic burden of newly diagnosed Alzheimer's disease in a medicare advantage population. Am. J. Alzheimers Dis. Other Dement. 2013, 28:384-392.
315. Sun W., Funakoshi H., Nakamura T. Overexpression of HGF retards disease progression and prolongs life span in a transgenic mouse model of ALS. J. Neurosci. 2002, 22:6537-6548.
316. Suzuki Y., Ruiz-Ortega M., Lorenzo O., Ruperez M., Esteban V., Egido J. Inflammation and angiotensin II. Int. J. Biochem. Cell Biol. 2003, 35:881-900.
317. Swanson G.N., Hanesworth J.M., Sardinia M.F., Coleman J.K., Wright J.W., Hall K.L., Miller-Wing A.V., Stobb J.W., Cook V.I., Harding E.C., Harding J.W. Discovery of a distinct binding site for angiotensin II (3-8), a putative angiotensin IV receptor. Regul. Pept. 1992, 40:409-419.
318. Tada R., Zhan H., Tanaka Y., Hongo K., Matsumoto K., Nakamura T. Intraventricular administration of hepatocyte growth factor treats mouse communicating hydrocephalus induced by transforming growth factor beta1. Neurobiol. Dis. 2006, 21:576-585.
319. Takeo S., Takagi N., Takagi K. Ischemic brain injury and hepatocyte growth factor. Yakugaku Zasshi 2007, 127:1813-1823.
320. Takeuchi E., Sato N., Shimamura M., Kurinami H., Takeda S., Shinohara M. Alleviation of aβ-induced cognitive impairment by ultrasound-mediated gene transfer of HGF in a mouse model. Gene Ther. 2008, 15:561-571.
321. Tchekalarova J.D., Georgiev V.P. Angiotensin peptides modulatory system: how is it implicated in the control of seizure susceptibility?. Life Sci. 2005, 76:955-970.
322. Tchekalarova J.D., Georgiev V.P. Ang II and Ang III modulate PTZ seizure threshold in non-stressed and stressed mice: possible involvement of noradrenergic mechanism. Neuropeptides 2006, 40:339-348.
323. 1 receptors. Brain Res. Bull. 2001, 56:87-91.
324. Thewke E.P., Seeds N.W. The expression of mRNAs for hepatocyte growth factor/scatter factor, its receptor c-met, and one of its activators tissue-type plasminogen activator show a systematic relationship in the developing and adult cerebral cortex and hippocampus. Brain Res. 1999, 821:356-367.
325. Thomas S.J., Grossberg G.T. Memantine: a review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias. Clin. Interv. Aging 2009, 4:367-377.
326. Thomas W.G., Mendelsohn F.A. Molecules in focus. Angiotensin receptors: form and function and distribution. Int. J. Biochem. Cell Biol. 2003, 35:774-779.
327. Thompson J., Dolcet X., Hilton M., Tolcos M., Davies A.M. HGF promotes survival and growth of maturing sympathetic neurons by PI-3 kinase- and MAP kinase-dependent mechanisms. Mol. Cell. Neurosci. 2004, 27:441-452.
328. Todd P.A., Heel R.C. Enalapril. A review of its pharmacodynamics and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 1986, 31:198-248.
329. Topper R., Gehrmann J., Banati R., Schwartz M., Block F., Noth J., Kreutzberg G.W. Rapid appearance of beta-amyloid precursor protein immunoreactivity in glial cells following excitotoxic brain injury. Acta Neuropathol. 1995, 89:23-28.
330. Tota S., Goel R., Pachauri S.D., Rajasekar N., Najmi A.K., Hanif K., Nath C. Effect of angiotensin II on spatial memory, cerebral blood flow, cholinergic neurotransmission, and brain derived neurotrophic factor in rats. Psychopharmacology (Berl.) 2013, 226:357-369.
331. Touyz R.M., Chen X., Tabet F., Yao G., He G., Quinn M.T., Pagano P.J., Schiffrin E.L. Expression of a functionally active gp91 phox-containing neurtrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: regulation by angiotensin II. Circ. Res. 2002, 90:1205-1213.
332. Trenkwalder P. The study on cognition and prognosis in the elderly (SCOPE) - recent analyses. J. Hypertens. 2006, 24:S107-S114.
333. Tsuboi Y., Kakimoto K., Akatsu H., Daikuhara Y., Yamada T. Hepatocyte growth factor in cerebrospinal fluid in neurologic disease. Acta Neurol. Scand. 2002, 106:99-103.
334. Tsuzuki N., Miyazawa T., Matsumoto K., Nakamura T., Shima K. Hepatocyte growth factor reduces the infarct volume after transient focal cerebral ischemia in rats. Neurol. Res. 2001, 23:417-424.
335. Tufekci K.U., Genc S., Genc K. The endotoxin-induced neuroinflammation model of Parkinson's disease. Parkinson's Dis. 2011, ID 487450.
336. Tulasne D., Foveau B. The shadow of death on the MET tyrosine kinase receptor. Cell Death Diff. 2008, 15:427-434.
337. Tyndall S.J., Patel S.J., Walikonis R.S. Hepatocyte growth factor-induced enhancement of dendritic branching is blocked by inhibitors of N-methyl-d-aspartate receptors and calcium/calmodulin-dependent kinases. J. Neurosci. Res. 2007, 85:2343-2351.
338. Tyndall S.J., Walikonis R.S. The receptor tyrosine kinase Met and its ligand hepatocyte growth factor are clustered at excitatory synapses and can enhance clustering of synaptic proteins. Cell Cycle 2006, 5:1560-1568.
339. Tyndall S.J., Walikonis R.S. Signaling by hepatocyte growth factor in neurons is induced by pharmacological stimulation of synaptic activity. Synapse 2007, 61:199-204.
340. Ultsch M., Lokker N.A., Godowski P.J., de Vos A.M. Crystal structure of the NK1 fragment of human hepatocyte growth factor at 2.0A resolution. Structure 1999, 6:1383-1393.
341. Unger T., Chung O., Csikos T., Culman J., Gallinat S., Gohlke P., Höhle S., Meffert S., Stoll M., Stroth U., Zhu Y.A. Angiotensin receptors. J. Hypertens. 1996, (Suppl. 14):S95-S103.
342. Van Belle E., Witzenbichler B., Chen D., Silver M., Chang L., Schwall R., Isner J.M. Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: the case for paracrine amplification of angiogenesis. Circulation 1998, 97:381-390.
343. Vanderheyden P.M. From angiotensin IV binding site to AT4 receptor. Mol. Cell. Endocrinol. 2009, 302:159-166.
344. Vaughan D.E. Angiotensin and vascular fibrinolytic balance. Am. J. Hypertens. 2002, 15(1 Pt2):3S-8S.
345. Vauquelin G., Michotte Y., Smolders I., Sarre S., Ebinger G., Dupont A., Vanderheyden P. Cellular targets for angiotensin II fragments: pharmacological and molecular evidence. J. Renin Angiotensin Aldosterone Syst. 2002, 3:195-204.
346. Villar-Cheda B., Valenzuela R., Rodriguez-Perez A.I., Guerra M.J., Labandeira-Garcia J.L. Aging-related changes in the nigral angiotensin system enhances proinflammatory and pro-oxidative markers and 6-OHDA-induced dopaminergic degeneration. Neurobiol. Aging 2012, 33(204):e1-e11.
347. von Bohlen und Halbach O. Angiotensin IV in the central nervous system. Cell Tissue Res. 2003, 31:1-9.
348. von Bohlen und Halbach O., Albrecht D. The CNS renin-angiotensin system. Cell Tissue Res. 2006, 326:599-616.
349. Wang T.W., Zhang H., Gyetko M.R., Parent J.M. Hepatocyte growth factor acts as a mitogen and chemoattractant for postnatal subventricular zone-olfactory bulb neurogenesis. Mol. Cell. Neurosci. 2011, 48:38-50.
350. Wayner M.J., Armstrong D.I., Phelix C.V., Wright J.W., Harding J.W. Angiotensin IV enhances LTP in rat dentate gyrus in vivo. Peptides 2001, 22:1403-1414.
351. Weidner K.M., Arakaki N., Hartmann G., Vandekereckhove J., Weingart S., Rieder H., Fonatsch C., Tsubouchi H., Hishida T., Daikuhara Y. Evidence for the identity of human scatter factor and human hepatocyte growth factor. Proc. Natl. Acad. Sci. U. S. A. 1991, 88:7001-7005.
352. Weidner K.M., Behrens J., Vandekerckhove J., Birchmeier W. Scatter factor: molecular characteristics and effect on the invasiveness of epithelial cells. J. Cell Biol. 1990, 111:2097-2108.
353. Weidner K.M., Di Cesare S., Sachs M., Brinkmann V., Behrens J., Birchmeier W. Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis. Nature 1996, 384:173-176.
354. Welchko R.M., Leveque X.T., Dunbar G.I. Genetic rat models of Parkinson's disease. Parkinson's Dis. 2012, article ID 128356, 6 pages.
355. Wexler R.R., Greenlee W.J., Irvin J.D., Goldberg M.R., Prendergast K., Smith R.D., Timmermans P.B. Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy. J. Med. Chem. 1996, 39:625-656.
356. White W.B., Weber M.A., Sica D., Bakris G.L., Perez A., Cao C., Kupfer S. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension 2011, 57:413-420.
357. Wilk S., Healy D.P. Glutamyl aminopeptidase (aminopeptidase A), the BP-1/6C3 antigen. Adv. Neuroimmunol. 1993, 3:195-207.
358. Witte M.E., Geurts J.G., deVries H.E., van der Valk P., van Horssen J. Mitochondrial dysfunction: a potential link between neuroinflammation and neurodegeneration?. Mitochondrion 2010, 10:411-418.
359. Wright J.W., Harding J.W. Important roles for angiotensin III and IV in the brain renin-angiotensin system. Brain Res. Rev. 1997, 25:96-124.
360. Wright J.W., Harding J.W. The brain angiotensin system and extracellular matrix molecules in neural plasticity, learning, and memory. Prog. Neurobiol. 2004, 72:263-293.
361. 4 receptor subtype as a target for the treatment of memory dysfunction associated with Alzheimer's disease. J. Renin Angiotensin Aldosterone Syst. 2008, 9:226-237.
362. 4 receptor system as a new target for the treatment of Alzheimer's disease. Drug Dev. Res. 2009, 70:472-480.
363. Wright J.W., Harding J.W. Brain renin-angiotensin: a new look at an old system. Prog. Neurobiol. 2011, 95:49-67.
364. Wright J.W., Harding J.W. Importance of the brain angiotensin system in Parkinson's disease. Parkinson's Dis. 2012, 2012. article ID 860923.
365. 1 receptor subtype in cardiovascular function. Peptides 1996, 17:1365-1371.
366. Wright J.W., Clemens J.A., Panetta J.A., Smalstig E.B., Weatherly L.A., Kramár E.A., Pederson E.S., Mungall B.H., Harding J.W. Effects of LY231617 and angiotensin IV on ischemia-induced deficits in circular water maze and passive avoidance performance in rats. Brain Res. 1996, 717:1-11.
367. Wright J.W., Kawas L.H., Harding J.W. A role for the brain RAS in Alzheimer's and Parkinson's diseases. Front. Endocrinol. 2013, 4. article 158.
368. Wright J.W., Kramár E.A., Myers E.D., Davis C.J., Harding J.W. Ethanol-induced suppression of LTP can be attenuated with an angiotensin IV analog. Regul. Pept. 2003, 113:49-56.
369. Wright J.W., Krebs L.T., Stobb J.W., Harding J.W. The angiotensin IV system: functional implications. Front. Neuroendocrinol. 1995, 16:23-52.
370. Wright J.W., Miller-Wing A.V., Shaffer M.J., Higginson C., Wright D.E., Hanesworth J.M., Harding J.W. Angiotensin II(3-8) (ANG IV) hippocampal binding: potential role in the facilitation of memory. Brain Res. Bull. 1993, 32:497-502.
371. 4 receptor subtype system to spatial learning. J. Neurosci. 1999, 19:3952-3961.
372. Wright J.W., Yamamoto B.J., Harding J.W. Angiotensin receptor subtype mediated physiologies and behaviors: new discoveries and clinical targets. Prog. Neurobiol. 2008, 84:157-181.
373. Wu D.C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., Choi D.K., Ischiropoulos H., Przedborski S. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 2002, 22:1763-1771.
374. Xiao G.H., Jeffers M., Bellacosa A., Mitsuuchi Y., Vande Woude G.F., Testa J.R. Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:247-252.
375. Xu K.P., Yu F.S. Cross talk between c-Met and epidermal growth factor receptor during retinal pigment epithelial wound healing. Invest. Ophthalmol. Vis. Sci. 2007, 48:2242-2248.
376. Yaari R., Corey-Bloom J. Alzheimer's disease. Semin. Neurol. 2007, 27:32-41.
377. Yamada T., Tsubouchi H., Daikuhara Y., Prat M., Comoglio P.M., McGeer P.L., McGeer E.G. Immunohistochemistry with antibodies to hepatocyte growth factor and its receptor protein (c-MET) in human brain tissues. Brain Res. 1994, 637:308-312.
378. 3-4-His-Pro-Phe (Norleual) can act as a hepatocyte growth factor/c-Met inhibitor. J. Pharmacol. Exp. Ther. 2010, 333:161-173.
379. Yasar S., Xia J., Yao W., Furberg C.D., Xue O.L., Mercado C.I., Fitzpatrick A.L., Fried L.P., Kawas C.H., Sink K.M., Williamson J.D., DeKosky S.T., Carlson M.C. Ginkgo evaluation of memory (GEM) study investigators. Neurology 2013, 81:896-903.
380. Yoshida S., Ymaguchi Y., Ltami S., Yoshikawa K., Tabata Y., Matsumoto K., Nakamura T. Neutralization of hepatocyte growth factor leads to retarded cutaneous wound healing associated with decreased neovascularization and granulation tissue formation. J. Invest. Dermatol. 2003, 120:335-343.
381. Youles M., Holmes O., Petoukhov M.V., Nessen M.A., Stivala S., Svergun D.I., Gherardi E. Engineering the NK1 fragment of hepatocyte growth factor/scatter factor as a MET receptor antagonist. J. Mol. Biol. 2008, 377:616-622.
382. Zanchetti A., Elmfeldt D. Findings and implications of the study on cognition and prognosis in the elderly (SCOPE) - a review. Blood Press. 2006, 15:71-79.
383. Zawada W.M., Banninger B.P., Thornton J., Marriott B., Cantu D., Rachubinski A.L., Das M., Griffin W.S., Jones S.M. Generation of reactive oxygen species in 1-methyl-4-phenylpyridinium (MPP+) treated dopaminergic neurons occurs as an NADPH oxidase-dependent two-wave cascade. J. Neuroinflamm. 2011, 8(129.e.):1-13.
384. Zou K., Gong J.S., Yanagisawa K., Michikawa M. A novel function of monomeric amyloid beta-protein serving as an antioxidant molecule against metal-induced oxidative damage. J. Neurosci. 2002, 22:4833-4841.
385. Zou K., Kim D., Kakio A., Byun K., Gong J.S., Kim J., Kim M., Sawamura N., Nishimoto S., Matsuzaki K., Lee B., Yanagisawa K., Michikawa M. Amyloid beta-protein (A{cyrillic}β)1-40 protects neurons from damage induced by (A{cyrillic}β)1-42 in culture and in rat brain. J. Neurochem. 2003, 87:609-619.
386. Zou K., Maeda T., Watanabe A., Liu J., Liu S., Oba R., Satoh Y., Komano H., Michikawa M. Abeta42-to-Abeta40- and angiotensin-converting activities in different domains of angiotensin-converting enzyme. J. Biol. Chem. 2009, 284:31914-31920.